Effect of the dual 5α-reductase inhibitor Pnu 157706 on the growth of Dunning R3327 prostatic carcinoma in the rat

Journal of Steroid Biochemistry and Molecular Biology

Volumn 64, Issue 3-4, 1998, Pages 193-198

  Zaccheo, T ^a   Giudici, D ^a   Di Salle, E ^a  

^a Res/Oncol Pharmacia Upjohn V   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; N [2,2,2 TRIFLUORO 1 PHENYL 1 (TRIFLUOROMETHYL)ETHYL] 3 OXO 4 AZA 5ALPHA ANDROST 1 ENE 17BETA CARBOXAMIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; STEROID 5ALPHA REDUCTASE;

ADRENAL GLAND; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASTRATION; CONTROLLED STUDY; HYPOPHYSIS; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; ORGAN WEIGHT; PROSTATE CARCINOMA; PROSTATE VENTRAL LOBE; RAT; SEMINAL VESICLE; TESTIS; THYMUS; TUMOR GROWTH; ANIMAL; CELL DIVISION; CHEMICAL STRUCTURE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; EPIDIDYMIS; ORGAN SIZE; PROSTATE; PROSTATE TUMOR; RAT STRAIN;

ANIMALIA;

ANDROSTENES; ANIMALS; ANTINEOPLASTIC AGENTS; CASTRATION; CELL DIVISION; DIHYDROTESTOSTERONE; ENZYME INHIBITORS; EPIDIDYMIS; MALE; MOLECULAR STRUCTURE; ORGAN SIZE; PROSTATE; PROSTATIC NEOPLASMS; RATS; RATS, INBRED STRAINS; SEMINAL VESICLES; TESTIS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0031596851     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(97)00157-X     Document Type: Article

References (30)

1. Ford L. G., Brawley O. W., Perlman J. A., Nayfield S. G., Johnson K. A., Kramer B. S. The potential for hormonal prevention trials. Cancer. 74:1994;2726-2733.
2. Hammond G. L. Endogenous steroid levels in the human prostate from birth to old age: A comparison of normal and disease tissues. J. Endocr. 78:1978;7-19.
3. Klein H., Bressel M., Kastendieck H., Voigt K. D. Quantitative assessment of endogenous testicular and adrenal sex steroids and of steroid metabolizing enzymes in untreated human prostatic cancerous tissue. J. Steroid Biochem. 30:1988;119-130.
4. Liao S., Liang T., Tymoczko J. L. Structural recognition in interactions of androgens and receptor proteins and in their association with nuclear components. J. Steroid Biochem. 3:1972;401-407.
5. di Salle, E., Giudici, D., Radice, A., Zaccheo, T., Ornati, G., Nesi, M., Panzeri, A., Délos, S. and Martin, P. M., PNU 157706, a novel dual type I and II 5α-reductase inhibitor. J. Steroid Biochem. Molec. Biol., 1998, this issue.
6. Isaacs J. T., Coffey D. S. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R3327-H adenocarcinoma. Cancer Res. 41:1981;5070-5075.
7. Geran R. I., Greenberg N. H., Mc Donald M. M., Schumacher A. M., Abbott B. J. Protocol for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep. 3:1972;1-103.
8. Isaacs J. T., Isaacs W. B., Feitz W. F. J., Scheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancer. Prostate. 9:1986;261-281.
9. Lamb J. C., Levy M. A., Johnson R. K., Isaacs J. T. Response of rat and human prostatic cancers to the novel 5α-reductase inhibitor, SKF 105657. Prostate. 21:1992;15-34.
10. Huggins C., Hodges C. V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1:1941;293-297.
11. Labrie F., Belanger A., Simard J., Labrie C., Dupont A. Combination therapy for prostate cancer. Cancer. 71:1993;1059-1067.
12. Vogelzang N. J., Kennealey G. T. Recent development in endocrine treatment of prostate cancer. Cancer. 70:1992;966-976.
13. Hsieh W.-S., Simons J. W. Systemic therapy of prostate cancer. New concepts from prostate cancer tumor biology. Cancer Treatment Rev. 19:1993;229-260.
14. Schröder F. H. 5α-Reductase inhibitors and prostatic disease. Clin. Endocrinol. 41:1994;139-147.
15. Andersson S., Russell D. W. Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc. Natl. Acad. Sci. USA. 87:1990;3640-3644.
16. Bonkhoff H., Stein U., Aumüller G., Remberger K. Differential expression of 5α-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate. 29:1996;261-267.
17. Silver R. I., Wiley E. L., Davis D. L., Thigpen A. E., Russell D. W., McConnell J. D. Expression and regulation of steroid 5α-reductase 2 in prostate disease. J. Urol. 152:1994;433-437.
18. Sutkowski D. M., Audia J. E., Goode R. L., Hsiao K. C., Leibovitch I. Y., McNulty A. M., Neubauer B. L. Responses of LNCaP prostatic adenocarcinoma cell cultures to LY 300502, a benzoquinolinone human type I 5α-reductase inhibitor. Prostate. 6 (Suppl.):1996;62-66.
19. Délos S., Iehlè C., Martin P. M., Raynaud J. P. Inhibition of the activity of basic 5α-reductase (type 1) detected in DU 145 cells and expressed in insect cells. J. Steroid Biochem. Molec. Biol. 48:1994;347-352.
20. Normington K., Russell D. W. Tissue distribution and kinetic characteristics of rat steroid 5α-reductase isozymes. Evidence for distinct physiological functions. J. Biol. Chem. 267:1992;19548-19554.
21. Brooks J. R., Berman C., Primka R. L., Reynolds G. F., Rasmusson G. H. 5α-Reductase inhibitory and anti-androgenic activities of some 4-azasteroids in the rat. Steroids. 47:1986;1-19.
22. Andersson S., Berman D. M., Jenkins E. P., Russell D. W. Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature. 354:1991;159-161.
23. Gormley G. J., Stoner E., Bruskewitz R. C., Imperato-McGinley J., Walsh P. C., McConnell J. D., Andriole G. L., Geller J., Bracken B. R., Tenover J. S., Darracott Vaughan E., Pappas F., Taylor A., Binkowitz B., Ng J. The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med. 327:1992;1185-1191.
24. Peters D. H., Sorkin E. M. Finasteride, a review of its potential in the treatment of benign prostatic hyperplasia. Drugs. 46:1993;177-208.
25. Brooks J. R., Berman C., Nguyen H., Prahalada S., Primka R. L., Rasmusson G. H., Slater E. E. Effect of castration, DES, flutamide, and the 5α-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R3327. Prostate. 18:1991;215-227.
26. Presti J. C., Fair W. R., Andriole G., Sogani P. C., Seidmon E. J., Ferguson D., Ng J., Gormley G. J. Multicenter, randomized, double-blind, placebo-controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J. Urol. 148:1992;1201-1204.
27. Andriole G., Lieber M., Smith J., Soloway M., Schroeder F., Kadmon D., DeKernion J., Rajfer J., Boake R., Crawford D., Ramsey E., Perreault J., Trachtenberg J., Fradet Y., Block N., Middleton R., Ng J., Ferguson D., Gormley G. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology. 45:1995;491-497.
28. Rittmaster R. S., Magor K. E., Manning A. P., Norman R. W., Lazler C. B. Differential effect of 5α-reductase inhibition and castration on androgen-regulated gene expression in rat prostate. Molec. Endocrinol. 5:1991;1023-1029.
29. Lamb J. C., English H., Levandoski P. L., Rhodes G. R., Johnson R. K., Isaacs J. T. Prostatic involution in rats induced by a novel 5α-reductase inhibitor, SK and F 105657: Role for testosterone in the androgenic response. Endocrinology. 130:1992;685-694.
30. Fleshner N. E., Fair W. R. Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br. J. Urol. 78:1996;907-910.